BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for BioNexus Gene Lab
BioNexus Gene Lab has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?